| 000 | 02024cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031227.0 | ||
| 008 | 150512s2014 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.28.Ph.D.2014.Mo.O | ||
| 100 | 0 | _aMohammed Gamal Eldin Fathallah | |
| 245 | 1 | 0 |
_aOcular manifestations of nephropathic cystinosi / _cMohammed Gamal Eldin Fathallah ; Supervised Neveen Abdelmonem Soliman , Akmal Abdelmonem Rizk , Ahmed Mohamed Badr |
| 246 | 1 | 5 | _aدراسة تأثر العين فى مرض السيستينوسيس الكلوى |
| 260 |
_aCairo : _bMohammed Gamal Eldin Fathallah , _c2014 |
||
| 300 |
_a143 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pediatrics | ||
| 520 | _aBackground: Nephropathic cystinosis is a rare genetic disease characterized by accumulation of the amino acid cystine in lysosomes throughout the body. Ocular manifestations, particularly corneal cystine crystal formation, remain a major complication of nephropathic cystinosis.Conclusion: Anterior segment ocular manifestations of nephropathic cystinosis are more frequent than posterior segment involvement, being uniformly present in almost all patients beyond infancy. Topical cysteamine therapy is effective in depleting cystine crystals from the avascular cornea. Nevertheless, there is a pressing need for long-acting cysteamine eye drops to enhance patient compliance and improve outcome | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCorneal cystine crystal scoring | |
| 653 | 4 | _aCysteamine eye drops | |
| 653 | 4 | _aNephropathic cystinosis | |
| 700 | 0 |
_aAhmed Mohamed Badr , _eSupervisor |
|
| 700 | 0 |
_aAkmal Abdelmonem Rizk , _eSupervisor |
|
| 700 | 0 |
_aNeveen Abdelmonem Soliman , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c50891 _d50891 |
||